PREOPERATIVE PILOT STUDY TO ASSESS SAFETY AND IMMUNOLOGICAL EFFECT OF PEMBROLIZUMAB (KEYTRUDA®) IN COMBINATION WITH PARICALCITOL WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH RESECTABLE PANCREATIC CANCER: